Yıl: 2020 Cilt: 24 Sayı: 3 Sayfa Aralığı: 221 - 229 Metin Dili: İngilizce DOI: 10.25179/tjem.2020-74861 İndeks Tarihi: 20-10-2020

Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience

Öz:
Objective: Adrenocortical cancer (ACC) is one of the rareendocrine system cancers that are aggressive. Despite surgicaltreatment, the mortality rate is quite high. This studyaimed to examine prognostic factors affecting survival in patientswith ACC, the role of dehydroepiandrosterone sulfate(DHEA-S), and the maximum standard uptake (SUVmax) valueson predicting mortality through the single-center data.Material and Methods: A total of 21 patients who were diagnosedwith adrenal cancer and followed from a single centerwere included in the study. Patients who survivedfollow-ups were included in the survived group (n=6), andthose who died were included in the dead group (n=15). Thedemographic, anatomical, pathological, and clinical characteristicsof the patients were analyzed. Positron emission tomography-computerized tomography imaging and SUVmaxvalues of adrenal masses were compared. The effect of allthese data on survival was examined. Results: The mortalityrate among patients with ACC was 71%. According tothe Kaplan-Meier survival analysis, the average life expectancywas 23.66±2.79 (95% CI=18.18-29.13) months. Themass size of the survived and dead groups was 9.2±3.82cm and 10.84±4.74 cm, respectively. The production rate ofadrenal hormone was higher in the dead group (p<0.01;80%). Moreover, the DHEA-S level and SUVmax values werestatistically significantly higher in the dead group (p<0.001;p<0.05, respectively). Although no metastases were observedin the survived group during follow-ups after the operation,distant metastases were observed in 8 people from thedead group (53%; p<0.05). Conclusion: The mortality ratewas very high in ACC despite surgical and medical treatments.The higher DHEA-S and SUVmax values may indicatethat the overall survival duration was low.
Anahtar Kelime:

Adrenokortikal Kanserlerde Sağ Kalıma Etki Eden Faktörler: Tek Merkez Deneyimi

Öz:
Amaç: Adrenokortikal kanser [adrenocortical cancer (ACC)], agresif seyreden nadir görülen endokrin sistem kanserlerindendir. Cerrahi tedaviye rağmen mortalitesi oldukça yüksektir. Bu çalışmada, ACC hastalarda sağ kalıma etki eden prognostik faktörleri dehidroepiandrosteron sülfat (DHEA-S) ve maksimum standart uptake (SUVmax) değerlerinin mortaliteyi ön görmedeki rolünü, tek merkez verileri üzerinden araştırmayı amaçladık. Gereç ve Yöntemler: Adrenal kanser tanısı almış tek merkezden takipli 21 hasta çalışmaya alındı. Takiplerde hayatta olanlar sağ olan grup (n=6), ölenler ölü olan grup (n=15) olarak kabul edildi. Hastaların demografik, anatomik, patolojik ve klinik özelliklerine bakıldı. Adrenal kitlelerin, pozitron emisyon tomografi görüntülemesi ile SUVmax değerleri karşılaştırıldı.Tüm bu verilerin sağkalım üzerine etkileri araştırıldı. Bulgular: ACC’li hastalarda mortalite oranı %71 olarak bulundu. Kaplan- Meier yaşam analizine göre ortalama yaşam süresi 23,66±2,79 (%95 GA=18,18-29,13) ay olarak bulundu. Sırasıyla, sağ olan ve ölü olan grubun kitle boyutu 9,2±3,82 cm ve 10,84±4,74 cm olarak bulundu. Adrenal hormon üretimi, ölü olan grupta daha yüksek oranda izlendi (p<0,01; %80). Ayrıca DHEA-S seviyesi ve SUVmax değeri ölü olan grupta istatistiksel olarak yüksek bulundu (sırasıyla p<0,001; p<0,05). Operasyon sonrası takiplerde sağ olan grupta hiç metastaz yokken, ölü olan grupta 8 kişide uzak metastaz saptandı (%53; p<0,05). Sonuç: ACC’de mortalite oranı, cerrahi ve medikal tedavilere rağmen oldukça yüksektir. DHEA-S seviyesinin ve SUVmax değerinin yüksek olması, genel sağkalım süresinin düşük olduğunu öngörebilir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Kerkhofs TMA, Verhoeven RHA, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, Van de Poll- Franse LV, Haak HR. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49:2579-2586. [Crossref] [PubMed]
  • 2. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12:667-680. [Crossref] [PubMed]
  • 3. Tauchmanovà L, Colao A, Marzano LA, Sparano L, Camera L, Rossi A, Palmieri G, Marzano E, Salvatore M, Pettinato G, Lombardi G, Rossi R. Adrenocortical carcinomas: twelve-year prospective experience. World J Surg. 2004;28:896-903. [Crossref] [PubMed]
  • 4. Osella G, Terzolo M, Borretta G, Magro G, Alí A, Piovesan A, Paccotti P, Angeli A. Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas). J Clin Endocrinol Metab. 1994;79:1532- 1539. [Crossref] [PubMed]
  • 5. Elaini AB, Shetty SK, Chapman VM, Sahani DV, Boland GW, Sweeney AT, Maher MM, Slattery JT, Mueller PR, Blake MA. Improved detection and characterization of adrenal disease with PET-CT. Radiographics. 2007;27:755-767. [Crossref] [PubMed]
  • 6. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B; German Adrenocortical Carcinoma Registry Group. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115:243-250. [Crossref] [PubMed]
  • 7. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, Sturgeon C. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113: 3130-3136. [Crossref] [PubMed] [PMC]
  • 8. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25:891-897. [Crossref] [PubMed]
  • 9. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X, Bertherat J. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91:2650- 2655. [Crossref] [PubMed]
  • 10.Lucon AM, Pereira MA, Mendonça BB, Zerbini MC, Saldanha LB, Arap S. Adrenocortical tumors: results of treatment and study of Weiss's score as a prognostic factor. Rev Hosp Clin Fac Med Sao Paulo. 2002;57:251-256. [Crossref] [PubMed]
  • 11.Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8:163-169. [Crossref] [PubMed]
  • 12.Weiss LM, Medeiros LJ, Vickery Jr AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13:202-206. [Crossref] [PubMed]
  • 13. Michalkiewicz E, Sandrini R, Figueiredo B, Miranda ECM, Caran E, Oliveira-Filho AG, Marques R, Pianovski MAD, Lacerda L, Cristofani LM, Jenkins J, Rodriguez-Galindo C, Ribeiro RC. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol. 2004;22:838-845. [Crossref] [PubMed]
  • 14.Chong S, Lee KS, Kim HY, Kim YK, Kim BT, Chung MJ, Yi CA, Kwon GY. Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls. Radiographics. 2006;26:1811-1824; discussion 1824-1826. [Crossref] [PubMed]
  • 15. Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Poultsides GA, Pawlik TM. Outcomes after resection of cortisol-secreting adrenocortical carcinoma. Am J Surg. 2016;211:1106-1113. [Crossref] [PubMed] [PMC]
  • 16.Keskin S, Taş F, Vatansever S. Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome. Urol Int. 2013;90:435-438. [Crossref] [PubMed]
  • 17.Dy BM, Strajina V, Cayo AK, Richards ML, Farley DR, Grant CS, Harmsen WS, Evans DB, Grubbs EG, Bible KC, Young WF, Perrier ND, Que FG, Nagorney DM, Lee JE, Thompson GB. Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol. 2015;22:146-151. [Crossref] [PubMed]
  • 18. Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, Pentheroudakis G; ESMO Guidelines Working Group. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii131-138. [Crossref] [PubMed]
  • 19. Baudin E, Leboulleux S, Al Ghuzlan A, Chougnet C, Young J, Deandreis D, Dumont F, Dechamps F, Caramella C, Chanson P, Lanoy E, Borget I, Schlumberger M. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer. 2011;2:363-371. [Crossref] [PubMed]
  • 20.Tritos NA, Cushing GW, Heatley G, Libertino JA. Clinical features and prognostic factors associated with adrenocortical carcinoma: Lahey Clinic Medical Center experience. Am Surg. 2000;66:73-79. [PubMed]
APA GÜVEN M, ŞİMŞEK M, TUZCU A (2020). Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience. , 221 - 229. 10.25179/tjem.2020-74861
Chicago GÜVEN MEHMET,ŞİMŞEK MEHMET,TUZCU ALPASLAN KEMAL Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience. (2020): 221 - 229. 10.25179/tjem.2020-74861
MLA GÜVEN MEHMET,ŞİMŞEK MEHMET,TUZCU ALPASLAN KEMAL Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience. , 2020, ss.221 - 229. 10.25179/tjem.2020-74861
AMA GÜVEN M,ŞİMŞEK M,TUZCU A Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience. . 2020; 221 - 229. 10.25179/tjem.2020-74861
Vancouver GÜVEN M,ŞİMŞEK M,TUZCU A Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience. . 2020; 221 - 229. 10.25179/tjem.2020-74861
IEEE GÜVEN M,ŞİMŞEK M,TUZCU A "Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience." , ss.221 - 229, 2020. 10.25179/tjem.2020-74861
ISNAD GÜVEN, MEHMET vd. "Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience". (2020), 221-229. https://doi.org/10.25179/tjem.2020-74861
APA GÜVEN M, ŞİMŞEK M, TUZCU A (2020). Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience. Turkish Journal of Endocrinology and Metabolism, 24(3), 221 - 229. 10.25179/tjem.2020-74861
Chicago GÜVEN MEHMET,ŞİMŞEK MEHMET,TUZCU ALPASLAN KEMAL Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience. Turkish Journal of Endocrinology and Metabolism 24, no.3 (2020): 221 - 229. 10.25179/tjem.2020-74861
MLA GÜVEN MEHMET,ŞİMŞEK MEHMET,TUZCU ALPASLAN KEMAL Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience. Turkish Journal of Endocrinology and Metabolism, vol.24, no.3, 2020, ss.221 - 229. 10.25179/tjem.2020-74861
AMA GÜVEN M,ŞİMŞEK M,TUZCU A Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience. Turkish Journal of Endocrinology and Metabolism. 2020; 24(3): 221 - 229. 10.25179/tjem.2020-74861
Vancouver GÜVEN M,ŞİMŞEK M,TUZCU A Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience. Turkish Journal of Endocrinology and Metabolism. 2020; 24(3): 221 - 229. 10.25179/tjem.2020-74861
IEEE GÜVEN M,ŞİMŞEK M,TUZCU A "Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience." Turkish Journal of Endocrinology and Metabolism, 24, ss.221 - 229, 2020. 10.25179/tjem.2020-74861
ISNAD GÜVEN, MEHMET vd. "Factors Affecting Survival in Adrenocortical Cancers: Single-Center Experience". Turkish Journal of Endocrinology and Metabolism 24/3 (2020), 221-229. https://doi.org/10.25179/tjem.2020-74861